Physician profile
Steven L Silverstone
NPI 1942279625
$9,051.61
in general payments reported to CMS, 2019-2025
23 companies · $1,249 in 2025
The $1,249 reported for 2025 was more than what 93% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,171 · 2020: $810 · 2021: $1,165 · 2022: $1,808 · 2023: $1,309 · 2024: $1,540 · 2025: $1,249.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,985 · Entertainment: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,985.31 |
| Entertainment | $112.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,950.35 | 2019-2025 | Misight Contact Lens, Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $1,179.38 | 2022-2025 | Infuse, Biotrue One Day, Infuse Multifocal |
| Alcon Vision LLC | $1,065.22 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Allergan, INC. | $728.29 | 2019-2021 | |
| Abbvie INC. | $717.59 | 2022-2025 | Vuity, Alphagan P |
| Johnson & Johnson Vision Care, INC. | $521.57 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $380.20 | 2020-2024 | |
| Kala Pharmaceuticals, INC. | $344.88 | 2019-2021 | |
| Sight Sciences, INC. | $326.37 | 2020-2022 | |
| Tarsus Pharmaceuticals, INC. | $280.14 | 2024-2025 | Xdemvy |
| Optos, INC. | $211.09 | 2020-2024 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
| Horizon Therapeutics Plc | $202.51 | 2022-2023 | Tepezza |
| Visionix USA, INC | $186.02 | 2022 | |
| Dompe US, INC. | $153.84 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $142.01 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $121.84 | 2025 | Izervay |
| Oyster Point Pharma, INC. | $100.00 | 2022-2023 | Tyrvaya |
| Lkc Technologies, INC. | $98.93 | 2024 | |
| Rxsight INC | $97.32 | 2024-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Optovue, INC. | $83.22 | 2019 | |
| Topcon Healthcare, INC. | $68.18 | 2023 | |
| Lumibird Medical INC. | $53.88 | 2019 | |
| Glaukos Corporation | $38.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Silverstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.